Among the most common yet undertreated complications of childbirth, postpartum depression has long resisted precise biological explanation — until now. A large-scale genomic study published in Nature, drawing on data from over 70,000 individuals, has identified SRA1, a regulator of steroid hormone signaling, as a genetically validated therapeutic target for the condition. The discovery does not promise an immediate cure, but it names something that has long eluded medicine: a specific molecular mechanism, rooted in the hormonal upheaval of birth itself, that can now be pursued with intention.
Scientists identify SRA1 as novel drug target for postpartum depression
Postpartum depression affects a significant proportion of women after childbirth, impacting maternal mental health and family wellbeing; this research aims to improve treatment options.